



ASX ANNOUNCEMENT

Lumos Completes A\$5.0 million Loan Facility

Key Highlights

- Formal documentation signed for the secured Loan Facility of A\$5.0 million with major shareholders Tenmile and Ryder Capital
- Provides funding, if required, as Lumos advances towards the grant of CLIA waiver for FebriDx®.
- Tenmile and Ryder Capital will each receive 7.5 million shares as payment for the Establishment and Service fees.

MELBOURNE, Australia (9 September 2025) – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, has today completed the definitive documentation for the A\$5.0 million secured Loan Agreement (“Loan Facility”) with major shareholders Tenmile Ventures Pty Ltd (“Tenmile”) and Ryder Capital Management Pty Ltd (“Ryder Capital”).

The Loan Facility will provide Lumos with working capital flexibility, if required, as it progresses towards the granting of a CLIA waiver from the U.S. FDA for its flagship test, FebriDx®. All drawdowns will be at the discretion of the Company and based on funding needs.

As part of the agreement, Tenmile and Ryder Capital will each receive 7.5 million Lumos shares in satisfaction of the Establishment and Service fees.

The Company has also extinguished the previous convertible note arrangement, with the unused second tranche of A\$4.0 million with Lind Global Fund II, and SBC Global Investment Fund now terminated.

Commenting on the announcement, Doug Ward, CEO of Lumos Diagnostics said: *“Securing this facility provides Lumos with the flexibility to continue progressing towards CLIA waiver and the broader commercialization of FebriDx®, while minimizing equity dilution for our shareholders. We are grateful for the ongoing commitment of Tenmile and Ryder Capital, whose support has been pivotal in enabling us to execute on our strategy and maintain momentum at this important stage.”*

The material terms of the Loan Facility are unchanged from those outlined in the ASX announcement on 17 July 2025. Please refer to “Appendix 1: Material Terms of the Proposed Loan Facility” in that announcement for the details.

Ends-

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics,

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Haley Chartres – Australia

HACK Director

haley@hck.digital

+61 423 139 163

Investor Contact:

George Kopsiaftis

IR Specialist, IR Department

ir@lumosdiagnostics.com

+61 409 392 687

Company Registered Office:

Lumos Diagnostics Holdings Ltd

Suite 2, Level 11

385 Bourke Street

Melbourne, VIC 3000

info@lumosdiagnostics.com

+61 3 9087 1598